Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 3, 2008. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and contains no financial performance data.
Material Changes
The filing details the Company's issued share capital as of February 29, 2008. No material changes to financial performance or operations are reported in this specific document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Important Facts for Investors
- Issued Share Capital: As of February 29, 2008, the Company had 5,982,845,318 Ordinary shares of 25p each.
- Treasury Shares: 504,194,158 Ordinary shares are held in Treasury.
- Total Voting Rights: The total number of voting rights is 5,478,651,160.
- Regulatory Use: The voting rights figure is designated for shareholders to calculate notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.